Drugs / cIPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03566940 | Jul 2018 → Aug 2019 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cIPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03566940 ↗ |
| Modality | Vaccine | “conventional Salk IPV (cIPV)” NCT03566940 ↗ |
| Route | Intramuscular | “for IM injection” NCT03566940 ↗ |